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Associated with Hematopoietic Recovery and
Increased Susceptibility to Bacterial Infections in
Patients with Thalassaemia Major Undergoing Matched
Related Hematopoietic Stem Cell Transplantation
Shanmugaapriya Sellathamby,1 Kavitha M. Lakshmi,1 Marc Busson,2 Auro Viswabandya,1
Biju George,1 Vikram Mathews,1 Mammen Chandy,1 Dominique Charron,2
Rajagopal Krishnamoorthy,3 Ryad Tamouza,3 Alok Srivastava1In this study, the impact of polymorphisms in the genes of proinflammatory (IL-b, TNF-a, IL-6, IFN-g), anti-
inflammatory (transforming growth factor [TGF]-b, IL-10, IL-Ra), and other immunoregulatory factors
(FcgRIIa, NOS3) along with the conventional risk factors on the rate of hematopoietic recovery and first
episodes of bacterial, viral, or invasive fungal infections in 102 patients with b-thalassaemia major who un-
derwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) with relatively uniform protocols
at our center from June 1995 to June 2004 with a minimum follow-up of at least 2 years were studied ret-
rospectively for 180 days after hematopoietic stem cell transplantation (HSCT). Our data show that (1) do-
nor IL-1RN*2/2 (hazard ratio [HR], 2.4; 95% confidence interval [CI], 1.17-5.09; P 5 .018) and FCgRIIA
14481G/G genotypes (HR, 3.1; 95% CI, 1.56-6.31; P 5 .001) increased the incidence of bacterial infection;
(2) fungal infection was increased in recipients with whose donors had IFN-g 1874T/T genotype (HR, 3.8;
95% CI, 1.08-13.62; P 5 .037); (3) time to neutrophil recovery was shorter in splenectomized patients
(HR, 3.1; 95% CI, 1.70-5.64; P\.001), donors without IL-10 -1082A, -819T, and -592A haplotype (HR, 1.6;
95% CI, 1.02-2.39; P 5 .039), and recipients with IFN-g 1874A/A genotype (HR, 1.6; 95% CI, 1.05-2.56;
P 5 .029); and (4) time to platelet recovery was shorter in patients with IL-10 -1082A/A genotype (HR,
1.8; 95% CI, 1.14-2.68; P 5 .010) and with donors having TNF-a -308G/G genotypes (HR, 1.8; 95% CI,
1.06-2.93; P5 .028). These data suggest that outcome after allogeneic stem cell transplantation could be af-
fected by many factors. The mechanisms by which they bring about such impact needs further evaluation.
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6/j.bbmt.2012.01.011lignant [1] and nonmalignant hematological diseases
[2]. Infections are a major cause of morbidity and mor-
tality in patients undergoing allo-HSCT despite use of
antibiotics and growth factors. Host defenses are pro-
foundly altered due to the conditioning regimen, the
cytopenia resulting from it, use of central venous cath-
eters, prolonged administration of immunosuppressive
drugs, and graft-versus-host disease (GVHD), if that
occurs. All these factors causing the breakdown of the
immune system could predispose transplantation re-
cipients to bacterial, fungal, and viral infections during
post-HSCT. However, despite having similar risk
profiles, only a subset of at-risk individuals has been re-
ported to develop infections. There is strong evidence
for polymorphisms in the gene regulatory regions ac-
counting for inter-individual differences in the degree
of their expression or their functional ability [3-5].1219
1220 Biol Blood Marrow Transplant 18:1219-1226, 2012S. Sellathamby et al.Because most of the identified risk factors for infect-
ions affect the recipient’s immune system, we
hypothesize that genetic variation resulting in
functional variations within key innate or adaptive
immune response elements of the immune system
could influence the rate of hematopoietic recovery
and susceptibility to infections during post-HSCT. A
number of functionally relevant single- nucleotide
polymorphisms in genes encoding components of im-
mune system-like inflammatory cytokines (IL-1, tumor
necrosis factor [TNF]-a, and IFN-g) [3], host defense
molecules (FcgRIIa, MBL2, and MPO), [4] and im-
mune modulators (IL1Ra) [5] have also been reported
to modify the levels of these mediators secreted or ex-
pressed, thereby possibly altering the rate of hemato-
poietic recovery [6] and immune responses resulting
in varied susceptibility to bacterial, viral, and fungal in-
fections [7,8]. We have correlated polymorphisms in
genes of cytokines, TNF-a, IL-1b, IL-6, IFN-g,
IL10, transforming growth factor-b, and other host de-
fense molecules, FcgRIIa, nitric oxide, and IL1Ra with
the time to neutrophil and platelet recovery and inci-
dence of infections in patients with thalassaemia major
who underwent matched related allo-HSCT.PATIENTS AND METHODS
Patients and Eligibility Criteria
One hundred twenty patients with b-thalassaemia
major who underwent allo-HSCT at our center from
June 1995 to June 2004 were included. Patients for
whom DNA samples were unavailable (n 5 18) were
excluded from the study. All donors were HLA identi-
cal sibling (n5 97) or other (n5 5) close family mem-
bers either father or mother of the recipient. The study
was approved by the institutional review board and in-
formed consent was obtained from the parents of all
children enrolled in this study.Endpoint Definitions
Engraftment or neutrophil recovery was defined as
the first of 3 consecutive days of an absolute neutrophil
count (ANC) of greater than 0.5  109/L [9]. Platelet
recovery to greater than 20 109/L was defined as the
day when the first of 2 consecutive platelet counts sat-
isfied the conditions as previously described [10].
Three patients died in the first 21 days after transplan-
tation without having achieved neutrophil recovery
and, therefore, were excluded from the engraftment
analysis.
Bacterial infections were documented on positive
culture from any sites—blood, urine, sputum, pus, ab-
scess, and central venous catheter [11]. Positive blood
cultures of common skin contaminants were docu-
mented as blood stream infection by performing atleast 2 consecutive blood cultures drawn on separate
occasions. Urine culture was considered to be signifi-
cant if the colony count was .100,000/mm3 or if the
colony count was \100,000/mm3 but considered to
be significant if the patient was already on antibiotics.
Sputum culture was significant in the presence of pul-
monary findings or x-ray infiltrates. The diagnosis of
tuberculosis was based on biopsy showing granulomas
positive for AFB and/or cultures being positive.
Cytomegalovirus (CMV) infection was defined as
2 consecutive positive DNA-based CMV PCR assays,
and CMV disease was defined as the demonstration of
CMV in biopsy specimen from different sites of in-
volvement as previously reported [12]. The diagnosis
of herpes simplex and zoster was made on clinical
grounds, whereas tissue invasion was proven on biopsy
and histology. Adenovirus antigen detection was based
on ELISA. All fungal infections were documented as
probable, possible, and proven fungal infections based
on the Centers for Disease Control criteria [13].
Gene Polymorphism Analysis
Genomic DNA was extracted from peripheral
blood leukocytes from patients and donors by standard
procedures. Previously published protocols for PCR
and restriction digestion were used to identify the in-
tron2 (13953 T/C) IL-1b polymorphism, promoter
region (-511 C/T) IL-1b polymorphism, and an
86-bp tandem repeat (VNTR) in intron2 of IL-1RA
[14]. Polymorphisms in the promoter regions of IL-6
and TNF-a gene, respectively, at -174 G/C and
-308 G/A positions and IL-10 promoter polymor-
phisms (-1082 G/A, -819 A/T, -592 A/C) consti-
tuting 6 different promoter haplotypes were
determined by CYTGEN cytokine genotyping trays
(One Lambda, Canoga Park, CA) [15]. Both 1869
T/C (codon 10) and 1915 G/C (codon 25) poly-
morphisms in exon1 of TGF-b gene and an intron2
polymorphism of IFN-g at position 1874 were also
screened using the above-mentioned kits in all the re-
cipient/donor pairs.
Genotyping for FCgRIIA 14481 A/G polymor-
phism was performed by allele-specific restriction en-
zyme digestion, as described by Jiang et al. [16]. The
G/T polymorphism in exon7 of NOS-3 gene (at po-
sition 894) in codon 298 was studied using the previ-
ously published protocol [17].
Statistical Analysis
Descriptive statistics were calculated for all vari-
ables. The predictive effect of recipient and donor
gene polymorphisms of proinflammatory (TNF-a,
IL-1b, IL-6, and IFN-g), anti-inflammatory
(IL-1Ra, IL-10, and TGF-b) and other host defense
molecules, FcgRIIa, nitric oxide were assessed for
the outcome of allo-HSCT by Cox proportional
Table 1. Details of Patients, Disease, and Transplantation
Protocol (n 5 102)
Recipient No. of Patients 102 (%)
Age, years
Median (range) 6.5 (1-24)
Sex
Male 64 (63)
Female 38 (37)
Disease stage
Class I 8 (8)
Class II 44 (43)
Class III 50 (49)
Splenectomy 16 (16)
Donor No. of Patients 102 (%)
Age, years
Median (range) 7 (1-42)
Sex
Male 56 (55)
Female 46 (45)
Female donor to male recipient 32 (31)
Sex-matched transplantations 58 (57)
ABO compatibility
ABO match 61 (60)
ABO major incompatibility 27 (27)
ABO minor incompatibility 14 (14)
Transplantation
Conditioning
Bu (16 mg/kg) Cy (200 mg/kg) + ALG 66 (65)
Bu (14 mg/kg) Cy (160 mg/kg) + ALG 6 (6)
Bu (600 mg/m2) Cy (200 mg/kg) alone 30 (29)
GVHD prophylaxis
CSA + short course MTX 102 (100)
Nucleated cell dose (108/kg)
Median (range) 4.4 (2.2-9.8)
ABO indicates blood group types; Bu, busulfan; Cy, cyclophosphamide;
ALG, anti-lymphocyte globulin; GVHD, graft-versus-host disease; CSA,
cyclosporine A; MTX, methotrexate.
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12021 42 63 84 06 27 48 69 8010
1.0
.8
.6
.4
.2
0.0
With splenectomy
Without splenectomy
P < .001
Cu
m
ul
at
ive
 ra
te
 o
f N
eu
tro
ph
il R
ec
ov
er
y
Figure 1. Cumulative rate of neutrophil recovery with respect to sple-
nectomy. Cumulative rate of neutrophil recovery was faster with a me-
dian of 13 days in patients who had undergone splenectomy before
transplantation compared to 16 days in those who had not (P\.001).
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ent/donor age and gender, sex mismatch (in particular,
female donor to male recipient), blood group types
(ABO) major incompatibility, nucleated cell doses ad-
ministered, splenectomy performed before transplan-
tation, and the risk category as per Pesaro criteria
[18]. Cox proportional hazard model was used to iden-
tify the predictive effect of immunogenetic variables in
the development of early infections (bacterial, viral,
and fungal) at day 180 and time to neutrophil and
platelet recovery posttransplantation. Multivariate
analyses were done using the forward stepwise proce-
dure to identify the independent predictor of each end-
point. All predictors that were significant (P\ .05) by
univariate analysis were included in multivariate anal-
ysis. All tests were 2-sided, and the type 1 error rate
was fixed at 0.05. Statistical analyses were performed
using the SPSS 11 software package.RESULTS
Patient and donor characteristics including age,
sex, stage of the disease, and details of the transplanta-
tion are shown in Table 1.Overall Outcome
Of the 102 patients evaluated, 96 (94%) attained an
ANC of .0.5  109/L. The median time to recover
a neutrophil count .0.5  109/L was 16 days (range,
8-33 days). Ninety-one patients (89%) reached a plate-
let count of.20 109/L. The median time to achieve
an unsupported platelet count .20  109/L was 28
days (range, 13-154 days). Of the 96 evaluable patients
for GVHD, 54 patients (56%) developed acute
GVHD grade I to IV.
At day 180 after transplantation, 79 patients
(77.45%) had experienced at least 1 episode of docu-
mented infection. Infections were documented at var-
ious sites as follows: bacterial infections—blood (n 5
41), central venous catheter (n 5 2), urinary tract
(n 5 7), and skin (n 5 1); viral infections—blood
(n 5 35), skin (n 5 4), oral (n 5 4), lung (n 5 2), gas-
trointestinal tract (n 5 3), and urinary tract (n 5 1);
fungal infections—lung (n 5 8) and blood (n 5 2).
Cumulative incidence of at least 1 bacterial, viral,
and fungal infection at day 180 was 50% (n 5 51),
48% (n 5 49), and 9.8% (n 5 10), respectively.
Of the 24 patients who died, infections were the
major cause for mortality in 9 (37.4%)—bacterial
(n 5 4; 16.6%), viral (n 5 3; 12.5%), and fungal (n 5
2; 8.3%).Engraftment—Recovery of Neutrophil and
Platelet Counts
Neutrophil recovery (ANC .0.5  109/L) was
faster with amedian of 13 days (range, 8-17 days) in pa-
tients who had undergone splenectomy before trans-
plantation compared with 16 days (range, 11-119
days) in those who had not (P\ .001; Figure 1). Donor
IL-10 and recipient IFN-g gene polymorphisms
Figure 2. Cumulative rate of neutrophil recovery with respect to IFN-
g1874 gene polymorphism in recipients. Cumulative rate of neutrophil
recovery was faster in recipients with IFN-g 1874 A/A genotype com-
pared to thosewith IFN-g1874 T/T1T/A genotypes (P5.010). (PIFN-
g - ‘‘P’’ represents patient or recipient.).
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with the IFN-g1874T/T1T/A genotype were associ-
ated with a delayed neutrophil recovery (33 days)
compared with those with the IFN-g 1874A/A geno-
type (21 days; P 5 .010; Figure 2). Donors with IL-10
-1082A, -819T, and -592A haplotype were associated
with a delayed neutrophil recovery (33 days) compared
with those without IL-10 -1082A, -819T, and -592A
haplotype (24 days; P5 .021). In multivariate analysis,
time to neutrophil recovery was shorter in splenectom-
ized patients (hazard ratio [HR], 3.1; 95% confidence
interval [CI], 1.70-5.64; P \ .001), donors without
IL-10 -1082A, -819T, and -592A haplotype (HR, 1.6;
95% CI, 1.02-2.39; P 5 .039), and recipients with
IFN-g 1874A/A genotype (HR, 1.6; 95% CI, 1.05-
2.56; P 5 .029; Table 2).
Time to platelet recovery was shorter in patients
with donors having TNF-a -308G/G genotype (27
days; range, 13-96 days) compared with those with
TNF-a -308A/A1G/A genotype (34 days; range, 15-
154 days; P5 .035). Similarly, time to platelet recovery
was shorter in patients aged\10 years (28 days; range,
13-96 days; P 5 .047) and those with IL-10 -1082A/ATable 2. Association of ImmunoregulatoryGenePolymorphisms in
Marker/Variables Genotypes/Variables
Neutrophil
Median Day
Splenectomy Yes 13 (8-
No 16 (11
rIFN-g +874 A/A 16 (10
T/T+T/A 16 (8-
dIL-10 -1082A, -819T, -592A haplotype Without ATA 16 (8-
With ATA 16 (10
HR indicates hazard ratio; CI, confidence interval.
aCox regression analysis; ‘‘r’’ represents a specific genotype in the recipient, agenotype (26 days; range, 13-52 days; P 5 .012) com-
pared with patients with age.10 years (32 days; range,
17-154 days) and those with IL-10 -1082G/G1G/A
genotypes (32 days; range, 15-154 days), respectively.
In multivariate analysis, time to platelet recovery was
shorter in patients with donors having TNF-a -308G/
G genotype (HR, 1.8; 95% CI, 1.06-2.93; P 5 .028)
and recipients with IL-10 -1082A/A genotype (HR,
1.8; 95% CI, 1.14-2.68; P 5 .010; Table 3).
Infections
Donors having FCgRIIA14481G/G (HR, 3.1;
95% CI, 1.56-6.31; P 5 .001) and IL-1RN*2/2
genotypes (HR, 2.4; 95% CI, 1.17-5.09; P 5 .018)
showed an increased risk of bacterial infections by
day 180 by multivariate analysis (Table 4A). Conven-
tional risk factors such as acute GVHD and ANC re-
covery were not found to be associated with the risk
of developing bacterial infections. However, when
the episodes of bacterial infections were categorized
into pre-engraftment and postengraftment periods
and included in the multivariate analysis after
results were obtained: (1) recipients having
FCgRIIA14481G/G genotype (HR, 2.7; 95% CI,
1.04-7.19; P 5 .041); (2) donors having
FCgRIIA14481G/G genotype (HR, 2.4; 95% CI,
1.03-5.82; P 5 .043); and (3) pre-engraftment period
(neutropenia) increased the risk of bacterial infections
(HR, 37.9; 95% CI, 14.58-98.86; P\ .001; Table 4B).
Among the conventional risk factors, the pre-
engraftment period (neutropenia) (HR, 6.1; 95% CI,
2.48-14.94; P\ .001) and acute GVHD overall grade
(HR, 2.1; 95% CI, 1.15-3.89; P 5 .017), grade 2 to 4
(HR, 2.4; 95% CI, 1.36-4.26; P 5 .003), and grade 3
to 4 (HR, 2.7; 95% CI, 1.34-5.28; P5 .005) increased
the risk of developing viral infections. None of the im-
munoregulatory markers were found to be associated
with the risk of developing viral infections. Presence
of IFN-g 1874T/T (HR, 3.8; 95% CI, 1.08-13.62;
P5 .037) genotype in the donors was found to increase
the risk of fungal infections. Among the conventional
risk factors, pre-engraftment period (neutropenia) in-
creased the risk of developing fungal infection (HR,
80.6; 95% CI, 13.78-472.05; P 5 .001), and acuteRecipients/Donors and SplenectomywithNeutrophil Recovery
Recovery Univariatea Multivariatea
s (Range) HR (95% CI) P value HR (95% CI) P value
17) 3.0 (1.69-5.42) < .001 3.1 (1.70-5.64) < .001
-33) Reference Reference
-21) 1.7 (1.08-2.60) .021 1.6 (1.05-2.56) .029
33) Reference Reference
24) 1.6 (1.02-2.38) .038 1.6 (1.02-2.39) .039
-33) Reference Reference
nd ‘‘d’’ represents a specific genotype in the donor.
Table 3. Association of Immunoregulatory Gene Polymorphisms in Recipients/Donors and Recipient Age with Platelet Recovery
Marker/Variables Outcome/Genotypes
Platelet Recovery Univariatea Multivariatea
Median Days (Range) HR (95% CI) P value HR (95% CI) P value
Recipient age <10 28 (13-96) 1.7 (0.98-2.81) .058 NS
>10 32 (17-154) Reference
dTNF-a-308 G/G 27 (13-96) 1.7 (1.02-2.78) .044 1.8 (1.06-2.93) .028
G/A+A/A 34 (15-154) Reference Reference
rIL-10-1082 A/A 26 (13-52) 1.7 (1.09-2.56) .016 1.8 (1.14-2.68) .010
G/G+G/A 32 (15-154) Reference Reference
HR indicates hazard ratio; CI, confidence interval; NS, not significant.
aCox regression analysis; ‘‘r’’ represents a specific genotype in the recipient, and ‘‘d’’ represents a specific genotype in the donor.
Biol Blood Marrow Transplant 18:1219-1226, 2012 1223Immunogenetic Factors Influence the Outcome of Allo-HSCTGVHD grade 3 to 4 showed a trend for developing
fungal infections (HR, 3.8; 95% CI, 0.92-16.08;
P 5 .065; Table 5).
Overall Survival
Recipient age .10 (HR, 3.6; 95% CI, 1.54-8.32;
P 5 .003) and sex mismatched transplantations (HR,
4.1; 95% CI, 1.46-11.74; P 5 .007) were the conven-
tional factors found to be associated with poor overall
survival in this study group. Recipient IL-10 and do-
nor IFN-g gene polymorphisms also influenced the
overall survival time. Donors with the IFN-g
1874T/T genotype (HR, 3.1; 95% CI, 1.24-7.85;
P5 .016) and recipients with the IL-10 -819T/T geno-
type (HR, 2.9; 95% CI, 1.13-7.54; P 5 .027) were
found to be associated with poor overall survival in
this cohort (Table 6).DISCUSSION
Several new findings emerge from these data.
Among the conventional factors evaluated, we ob-
served a faster rate of ANC .0.5  109/L recovery
in splenectomized patients, as has been previously
reported, where the recovery of peripheral granulo-
cytes (to levels of 200, 500, and 1,000/mm3) and pla-
telets (levels of 50 and 100  103/mm3) were shown
to occur rapidly in the splenectomy group compared
to the nonsplenectomy group after transplantation
[19]. Delayed recovery may also be related to hyper-
splenism posttransplantation. Splenomegaly in pa-Table 4A. Association of Immunoregulatory Gene Polymorphism
Day 180
Marker Genotypes
Bacterial Infection
Yes No H
dIL-1Ra IL-1RN*2/2 9 4 2.
Others 41 47
rFcgRIIA +4481 A/G +G/G 41 26 2.
A/A 9 23
dFcgRIIA +4481 A/G+G/G 39 23 2.
A/A 12 27
HR indicates hazard ratio; CI, confidence interval; NS, not significant.
aCox regression analysis; ‘‘r’’ represents a specific genotype in the recipient, atients with b-thalassaemia might be the cause for the
delayed rate of neutrophil recovery in our cohort of pa-
tients because excessive sequestration of infused stem
cells in the spleen of patients with splenomegaly has
been shown [20]. This association between sple-
nectomy and faster ANC recovery in patients with
b-thalassaemia undergoing allo-HSCT has not been
previously reported. However, splenectomy does not
affect overall survival among these patients (data not
shown), as reported in our previous study, which had
analyzed the impact of pretransplantation splenectomy
only in patients with class III thalassaemia [21].
Our data also show that both recipient and donor
IL-10 gene polymorphisms affect hematopoietic re-
covery. Presence of donor IL-10 -1082A, -819T, and
-592A haplotype, which is associated with lower levels
of IL-10 and presence of recipient IL-10 -1082G/
G1G/A genotype associated with higher and interme-
diate levels [22] correlated with delayed neutrophil and
platelet recovery, respectively, in these study patients.
IL-10 genotypes contributing to lower levels of IL-10
hampering neutrophil recovery may explain the neces-
sity of the activated donor T cells in the bone marrow
innoculum is not only needed to exhibit the GvL effect
to prevent relapse but also to improve neutrophil en-
graftment with their source of cytokines (IL-10) by
suppressing the inhibitory cytokines of granulopoiesis
(IFN-g and TNF-a) produced by the residual recipi-
ent cells after conditioning [23].
From the observation of recipient IL-10 genotypes
(higher levels) impeding platelet recovery, we mays in Recipients and Donors with Bacterial Infections up to
Univariatea Multivariatea
R (95% CI) P value HR (95% CI) P value
1 (1.02-4.35) .045 2.4 (1.17-5.09) .018
Reference Reference
7 (1.31-5.56) .007 NS
Reference
6 (1.36-4.96) .004 3.1 (1.56-6.31) .001
Reference Reference
nd ‘‘d’’ represents a specific genotype in the donor.
Table 4B. Association of Immunoregulatory Gene Polymorphisms in Recipients and Donors with Bacterial Infections up to Day
180 with Episode of Bacterial Infections Categorized into Pre-Engraftment and Postengraftment Time Period
Marker/Variable Genotypes/Variables
Bacterial
Infection Univariatea Multivariatea
Yes No HR (95% CI) P value HR (95% CI) P value
Time of episode Pre-engraftment 32 3 21.3 (10.59-42.83) <.001 37.9 (14.58-98.86) < .001
Postengraftment 19 48 Reference Reference
dIL-1Ra IL-1RN*2/2 9 4 2.1 (1.02-4.35) .045 NS
Others 41 47 Reference
rFcgRIIA +4481 A/G+G/G 41 26 2.7 (1.31-5.56) .007 2.7 (1.04-7.19) .041
A/A 9 23 Reference Reference
dFcgRIIA +4481 A/G+G/G 39 23 2.6 (1.36-4.96) .004 2.4 (1.03-5.82) .043
A/A 12 27 Reference Reference
HR indicates hazard ratio; CI, confidence interval; NS, not significant.
aCox regression analysis; ‘r’ represents a specific genotype in the recipient and ‘d’ represents a specific genotype in the donor.
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(T cells) that form the possible source of IL-10 may
influence platelet recovery. Previous reports showing
the IL-10 role on related suppression of IL-1b
[24,25] production, which induces megakaryocyte
colony- forming units from murine and human
hematopoietic cells [26] could also form the support-
ing evidence for our observation. Recombinant IL-
10 has also been shown to decrease platelet counts
and hemoglobin levels when administered to normal
healthy adult volunteers [27]. There are also other re-
ports of cytokines produced by lymphocytes and mac-
rophages (IFN-g and TNF-a) of recipients after bone
marrow transplantation having inhibitory effects on
hematopoiesis [28] thereby supporting our findings
of recipient IFN-g 1874T/T1T/A genotypes associ-
ated with higher levels of IFN-g correlating with de-
layed neutrophil recovery (Table 2).
Although the role of residual cells of recipients be-
ing the source of proinflammatory cytokines is evident
from several in vivo studies, the recipient cells being
the source of IL-10 are speculative. Nevertheless, var-
ious results of previous clinical correlations [29] con-
firm the principle that the recipient response is
critical in bone marrow transplantation outcome dur-
ing the early posttransplantation period.
Our data further show, we believe for the first time,
the possible role of IL-1RN*2/2 and IFN-g 1874T/T
genotypes and also confirms the role of FCgRIIATable 5. Association of Immunoregulatory Gene Polymorphisms i
with Episode of Fungal Infections Categorized into Pre-Engraftmen
Marker/Variable Genotypes/Variables
Fungal Infection
Yes No
Time of episode Pre-engraftment 5 4
Postengraftment 5 88
aGVHD 3-4 Yes 3 10
No 5 78
dIFN-g +874 T/T 4 12
T/A + A/A 6 80
HR indicates hazard ratio; CI, confidence interval; NS, not significant; aGVHD
aCox regression analysis; ‘‘r’’ represents a specific genotype in the recipient, a14481G allele in infections [8] among patients with
b-thalassaemia undergoing allo-HSCT. Donor IL-
1RN*2/2 genotype associated with high serum levels
of IL-1Ra [14] and FCgRIIA 14481G allele account-
ing for reduced receptor affinity and specificity for
IgGs [4,30] were found to significantly increase the
risk of bacterial infections by day 180 (HR, 3.1; 95%
CI, 1.56-6.31; P 5 .001; Table 4A). It is possible that
polymorphism in IL-1RA and FCgRIIA genes of the
donors make recipients of HSCT susceptible to
more bacterial infection during the early posttrans-
plantation period by antagonizing IL-1b produced
by host defense cells [5] and decreasing the phagocytic
activity [31], respectively. Observation of recipient
FCgRIIA14481G allele increasing the risk of bacterial
infection during the pre-engraftment period
(Table 4B) emphasizes the role of phagocytes of recip-
ient origin in conferring protection against bacterial
infection during the early posttransplantation period
before engraftment. These results were also consistent
with the previous reports [8].
Donor IFN-g 1874T/T genotype associated with
higher levels of IFN-g [22] was found to be associated
with increased incidence of fungal infections. These
results seem to be discrepant from the previous reports
showing increased resistance for invasive fungal infec-
tions on administration of recombinant IFN-g [32].
However, no correlation with IFN-g genotypes with
incidence of fungal infections has been reportedn Recipients and Donors with Fungal Infections up to Day 180
t and Postengraftment Time Period
Univariatea Multivariatea
HR (95% CI) P value HR (95% CI) P value
80.6 (13.78-472.05) .001 NS
Reference
3.8 (0.92-16.08) .065 NS
Reference
3.8 (1.08-13.62) .037 NS
Reference
, acute graft-versus-host disease.
nd ‘‘d’’ represents a specific genotype in the donor.
Table 6. Association of Immunoregulatory Gene Polymorphisms in Recipients and Donors and Overall Survival after HLA Iden-
tical HSCT in Patients with b-Thalassemia Major
Marker Genotype
Events Univariatea Multivariatea
Yes No HR (95% CI) P value HR (95% CI) P value
Recipient age >10 11 13 3.4 (1.52-7.62) .003 3.6 (1.54-8.32) .003
<10 13 65 Reference Reference
Donor age >10 13 21 2.6 (1.16-5.78) .021 NS
<10 11 57 Reference
Sex mismatched Yes 19 39 3.1 (1.17-8.41) .023 4.1 (1.46-11.74) .007
No 5 39 Reference Reference
Splenectomy Yes 8 8 3.1 (1.34-7.33) .009 NS
No 16 70 Reference
rIL-10-819 T/T 7 7 3.5 (1.43-8.42) .006 2.9 (1.13-7.54) .027
T/C+C/C 17 70 Reference Reference
dIFN-g +874 T/T 7 9 2.7 (1.12-6.54) .027 3.1 (1.24-7.85) .016
T/A+A/A 17 69 Reference Reference
dIL-1Ra IL-1RN*2/2 6 7 3.0 (1.17-7.54) .022 NS
Others 17 71 Reference
HSCT indicates hematopoietic stem cell transplantation; HR, hazard ratio; CI, confidence interval; NS, not significant.
aCox regression analysis; ‘‘r’’ represents a specific genotype in the recipient, and ‘‘d’’ represents a specific genotype in the donor.
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g1874T/T genotype was not shown to be an indepen-
dent risk factor regardless of other conventional risk
factors such as neutropenia and acute GVHD grade
3 to 4 for fungal infections (Table 5).
Overall survival was found to be influenced by
factors that have been known to be the conventional
risk factors for acute GVHD such as increased age of
the recipient and sex mismatched transplantations
(Table 6). Donor IL-1RN*2/2 genotype associated
with bacterial infection did not independently influ-
ence overall survival in multivariate analysis. Also sple-
nectomy did not influence overall survival as
previously reported in class III thalassaemia patients
[21] despite it had shortened the time to ANC recovery
in this study group. From this study, we could also en-
visage that these results were not biased toward worse
outcomes in class III patients alone.
Because the polymorphisms in the genes selected
for evaluation in this study have also been known to
modify the level or functions of the mediators involved
in regulating immune response, identification of
a genetic polymorphism that influences infectious out-
come after HSCT has important implications for pre-
transplantation and posttransplantation care, and may
also have implications for the management of other
immune-compromised patients. However, unfortu-
nately, gene polymorphisms in other immune response
molecules such as MBL2, MASP2 [7,33], TLR4 [34],
IL23R [35], TLR1, TLR6 [36], CXCL10 [37], and
plasminogen [38] that have been previously reported
to be associated with infections could not be included
in this analysis due to insufficiency of DNA in these
consecutive patient/donor pairs for genotyping of
these immunoregulatory markers.
In our study, regardless of immunoregulatory fac-
tors included, various possible risk factors of infections
in post-allo-HSCT like neutropenia, acute GVHD,cell dose, and type of conditioning regimen were also
tested for the association with the development of in-
fections. However, CMV serostatus that has been pre-
viously reported to be associated with an increased risk
for infectious complications in patients with post-
allo-HSCT was not included in this study owing to
high seroprevalence of CMV IgG in the Indian popu-
lation [39]. Moreover, more than 98% of our recipi-
ents are also found to be CMV-positive.
This is the first study to comprehensively evaluate
the role of a large number of immunogenetic markers
with engraftment, bacterial, viral, and fungal infections
in HLA identical sibling transplantation in a cohort of
patients with a single nonmalignant genetic disorder.
The data obtained enhances our understanding of
the pathogenesis of infections and mechanisms of
host defenses after allo-HSCT but may also allow for
therapeutic decisions to be individualized.ACKNOWLEDGMENTS
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